91AV

Dr Jacob Bush is a Director in the Chemical Biology Department at GSK and sits on the leadership team of the GSK-Francis Crick Institute Biomedical LinkLabs collaboration.  Prior to joining GSK, Jake completed a degree in chemistry from the University of Oxford and a DPhil in chemical biology in the laboratory of Professor Christopher Schofield. With an interest for translational science, he joined GSK in 2015 to explore ways to accelerate drug discovery through innovations in chemical biology and machine learning. Recently, the GSK-Crick team received an EPSRC Prosperity Partnership grant to build a Systems Chemical Biology Platform that brings together reactive fragments, chemoproteomics, high-content biology and AI/ML. The platform is being applied in disease relevant models to expand the liganded proteome and generate insights into opportunities for therapeutic intervention.

Dr. Nir London completed his PhD in computational structural biology at the Hebrew University in 2012. He then pursued a post-doctoral fellowship with Brian Shoichet at UCSF where he developed a pioneering virtual screening platform for covalent inhibitor discovery. In 2015 Dr. London joined the Weizmann Institute of Science, where he is currently the Alan and Laraine Fischer Career Development Chair in the Dept. of Chemical and Structural Biology. Dr. London’s lab is focused on covalent chemical biology and drug discovery and is developing new technologies to discover and functionalise covalently acting compounds. His honors include amongst others the Alon fellowship, the EFMC award for young medicinal chemist in academia and the ICBS award for young chemical biologist.